StemCell Therapy

Here are the top stories covered by DocWire Newsthis week in the Hematology & Oncology section. This week, a report indicated that where you live impacts your chances of surviving lung cancer, ruxolitinib is associated with worsening cardiometabolic health, and more.

Men with theBRCA2mutation have an increased risk ofprostate cancercompared with non-BRCA2carriers and should undergo regular prostate-specific antigen testing, according to interim research from the IMPACT study, presented at the National Cancer Research Institute 2019 Cancer Conference. The results were also published inEuropean Urology.

In the past decade, newlung cancercases have decreased by 19% and five-year survival has increased by 26%, according to a promising report from theAmerican Lung Association. Despite this,lung cancerremains the leading cause of death in the United States, and the chance of surviving the disease is largely dictated by where a person lives.

Secondary surgical cytoreduction followed by chemotherapy does not extend overall survival (primary endpoint) compared with chemotherapy alone in patients with platinum-sensitive, recurrent ovarian cancer, according to a study published inThe New England Journal of Medicine.

Melanoma of the eye may soon be detected using a simple test, according to a study thatappeared inTranslational Vision Science & Technology.

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms, is associated with worseningcardiometabolic health, according to an article published inScientific Reports.

In case you missed it, more hem/onc headlines are featured below:

Continue reading here:
Hem/Onc Roundup: BRCA2 Mutation and Prostate Cancer, Cancer Drug Affects Cardio Health, and more - DocWire News

This entry was posted on November 18, 2019 at 7:45 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |